Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 6Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Liver Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × tivozanib × Clear all
NCT01478594 2015-07-08

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

AVEO Pharmaceuticals, Inc.

Phase 2 Completed
265 enrolled 34 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡